Psychiatr Serv 58:85-91, January 2007
doi: 10.1176/appi.ps.58.1.85
© 2007 American Psychiatric Association
Patterns of Psychotropic Drug Prescription for U.S. Patients With Diagnoses of Bipolar Disorders
Ross J. Baldessarini, M.D.,
Leslie Leahy, Ph.D.,
Stephen Arcona, Ph.D.,
Douglas Gause, Dr.P.H.,
Winnie Zhang, M.P.H. and
John Hennen, Ph.D.
OBJECTIVE: Bipolar disorders are prevalent major illnesses with high rates of morbidity, comorbidity, disability, and mortality. A growing number of psychotropic drugs are used to treat bipolar disorder, often off-label and in untested, complex combinations. METHODS: To quantify utilization rates for psychotropic drug classes, this study used the 2002-2003 U.S. national MarketScan research databases to identify 7,760 persons with ICD-9 bipolar disorder subtypes. Survival analysis was used to estimate times until initial monotherapies were augmented, changed, or discontinued. RESULTS: The most commonly prescribed first drug class was antidepressants (50% of patients), followed by mood stabilizers (25%: anticonvulsants, 17%, and lithium, 8%), sedatives (15%), and antipsychotics (11%). At study midpoint only 44% of patients were receiving monotherapy. Those receiving monotherapy were ranked by initial drug prescribed and percentage of patients (bipolar I and bipolar II): antidepressants (55% and 65%), lithium (51% and 41%), antipsychotics (32% and 31%), anticonvulsants (28% and 29%), and sedatives (28%, 25%). Median time to adding another psychotropic was 2.5-times less than median time to changing the initial treatment (16.4 compared with 40.9 weeks), and stopping was rare. Median weeks until therapy was changed in any way for 25% of patients was as follows: lithium, 29 weeks; antidepressants, 13; anticonvulsants, 13; antipsychotics, 13; and sedatives, 9. CONCLUSIONS: Antidepressants were the first-choice agent twice as often as mood stabilizers. Lithium was sustained longer than monotherapy with other mood stabilizers. Time to augmentation was much shorter than time to change or discontinuation.
Related Article:
-
January 2007: This Month's Highlights
Psychiatr Serv 2007 58: 7.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. A. Frye, G. Helleman, S. L. McElroy, L. L. Altshuler, D. O. Black, P. E. Keck Jr., W. A. Nolen, R. Kupka, G. S. Leverich, H. Grunze, et al.
Correlates of Treatment-Emergent Mania Associated With Antidepressant Treatment in Bipolar Depression
Am J Psychiatry,
February 1, 2009;
166(2):
164 - 172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.C. Nixon, M.W. Doak, H. Crozier, D.P. Crooks, and W.S. Waring
Patterns of antiepileptic drug overdose differ between men and women: admissions to the Edinburgh Poisons Unit, 2000-2007
QJM,
January 1, 2009;
102(1):
51 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Depp, V. D. Ojeda, W. Mastin, J. Unutzer, and T. P. Gilmer
Trends in Use of Antipsychotics and Mood Stabilizers Among Medicaid Beneficiaries With Bipolar Disorder, 2001-2004
Psychiatr Serv,
October 1, 2008;
59(10):
1169 - 1174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Baldessarini, H. Henk, A. Sklar, J. Chang, and L. Leahy
Psychotropic Medications for Patients With Bipolar Disorder in the United States: Polytherapy and Adherence
Psychiatr Serv,
October 1, 2008;
59(10):
1175 - 1183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Young and J. M. Hammond
Lithium in mood disorders: increasing evidence base, declining use?
The British Journal of Psychiatry,
December 1, 2007;
191(6):
474 - 476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
How Is Bipolar Disorder Treated in Real Life?
Journal Watch Psychiatry,
March 12, 2007;
2007(312):
3 - 3.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2007
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
